The Influence of Five Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer.
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Exemestane (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2012 Planned end date changed from 1 Oct 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.